Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine (Q38409647)

2 September 2017

Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine (English)

1 reference

2 September 2017

1 reference

Tim Heise

1

1 reference

2 September 2017

Ulrike Hövelmann

2

1 reference

2 September 2017

Leszek Nosek

3

1 reference

2 September 2017

Lidia Hermanski

4

1 reference

2 September 2017

Susanne G Bøttcher

5

1 reference

2 September 2017

Hanne Haahr

6

1 reference

2 September 2017

language of work or name

English

0 references

publication date

18 June 2015

1 reference

Expert Opinion on Drug Metabolism & Toxicology

2 September 2017

1 reference

2 September 2017

11

1 reference

2 September 2017

1193-1201

1 reference

2 September 2017

8

1 reference

Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy

2 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1058779

To: Scholtz HE, Pretorius SG, Wessels DH, Becker RHA (2005) Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 48:1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1058779

Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1058779

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1058779

Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1058779

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1058779

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1058779

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1058779

The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in i

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1058779

Insulin stacking versus therapeutic accumulation: understanding the differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1058779

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1058779

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1058779

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1058779

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1058779

Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1058779

10.1517/17425255.2015.1058779

21 January 2018

Identifiers

DOI

1 reference

release_herdkesfovaqtk7d3qgltgz2l4

2 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/herdkesfovaqtk7d3qgltgz2l4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference